The Weinberg Group (now ProPharma Group) Adds Experts to Team

October 3, 2018

WASHINGTON, DC – OCTOBER 3, 2018 – The Weinberg Group (now ProPharma Group), is growing. In addition to people, the company has also expanded its capabilities. Building upon its role as the most science minded of all firms in its space, the company welcomed the following senior-level staff members to its team, thus expanding its ANDA, medical device, and clinical development capabilities.

Bryce Whited, Ph.D.

Vice President, Medical Devices

Dr. Whited is an expert in all phases of the development, approval, and marketing of medical devices and combination products. He has extensive hands-on experience with U.S. regulatory submissions (IDE, PMA, 510(k), de novo, and HUD/HDE), change control, risk management, nonclinical testing, and clinical trial design. Prior to joining the company, he was a lead scientific reviewer at the FDA, and held senior regulatory positions at Biotronik and Contego Medical.

Chad Oh, M.D.

Vice President, Clinical Development

Dr. Oh consults on the clinical and regulatory development of vaccines, biologics and small molecules.  He has handled global development programs across various therapeutic areas, including autoimmune diseases, respiratory diseases, infectious diseases, cancer, CNS, and rare/orphan diseases.  Dr. Oh has effectively managed multiple submissions to U.S., European, and Asian regulatory authorities.  His vast knowledge acquired through his medical, academic, and industry posts provides Dr. Oh with the unique expertise to guide the company’s clients in all phases of clinical development as well as the implementation of successful regulatory strategies.

Rona LeBlanc-Rivera, Ph.D.

Senior Director

Dr. LeBlanc-Rivera has over 18 years of Pharmaceutical experience with specific concentration in generics, handling product launches, market re-introductions, life cycle maintenance and drug shortage mitigation strategies. She has successfully managed the compilation, review, and maintenance of ANDA, DMF, and NDA submissions. Her previous experience as an FDA CMC reviewer (biologics and small molecule generic drugs) has provided her with the knowledge to minimize the number of FDA deficiencies received by a company. Dr. LeBlanc-Rivera’s role within the company includes providing regulatory support to its clients.

The company is still working to fill a number of positions and invites interested candidates to submit their CV and cover letter. Additional information and a list of current openings is available on the company’s website.




Company News

October 3, 2018

ProPharma Group Celebrates 13th Anniversary

This month, ProPharma Group enters its 13th year in the pharmaceutical, biotechnology, and medical device industries, and we couldn’t be more thrilled to see what the year has in store for us. Built...

Read More

October 3, 2018

The Weinberg Group to Sponsor and Participate in Linking Leaders Roundtable Series

Linking Leaders’ Clinical Quality roundtable series provides pharmaceutical and biotech executives a forum to share insights and experiences, benchmark progress, and collaborate on solutions with...

Read More

October 3, 2018

ProPharma Group Announces the Acquisition of The Weinberg Group

Overland Park, KS — ProPharma Group, a portfolio company of Linden Capital Partners, announces the acquisition of Washington D.C.-based The Weinberg Group Inc. The Weinberg Group is a leading...

Read More